药物洗脱支架与覆膜支架在血液透析血管通路流出道干预中的比较
单中心回顾性研究比较药物洗脱支架(DES)与覆膜支架(SG)治疗血液透析血管通路流出道狭窄。共156例患者(DES 60例,SG 106例)。两组均显著减少靶病变干预次数并延长无干预时间,但12个月一期、辅助一期和二期通畅率无显著差异。
要点
- DES与SG均较普通球囊血管成形术显著降低靶病变干预率并延长无干预间期。
- DES与SG在12个月一期、辅助一期和二期通畅率上无显著差异。
- DES可作为流出道狭窄的潜在替代选择,尤其在静脉汇合处避免SG的流出道遮挡。
核心结论
- DES与SG均显著降低靶病变干预率并延长无干预间期,但两组总体通畅率无显著差异。
研究设计与样本
- 单中心回顾性研究,共纳入156例血液透析血管通路流出道狭窄患者,DES组60例,SG组106例。
主要发现
- DES组年均靶病变干预次数从2.4降至0.7(p<0.001),中位无干预时间从4个月延长至10个月(p<0.001)。
- SG组年均靶病变干预次数从1.3降至0.7(p<0.001),中位无干预时间从4个月延长至13个月(p<0.001)。
- 12个月时DES组一期、辅助一期、二期通畅率分别为49.9%、78.2%、96.7%,SG组分别为58.8%(p=0.198)、72.3%(p=0.264)、96.9%(p=0.877)。
临床怎么用
- DES可作为血液透析血管通路流出道狭窄的标签外替代选择,尤其在静脉汇合处避免SG的流出道遮挡。
局限性
- 单中心回顾性设计可能引入选择偏倚,且样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hemodialysis vascular accesses are susceptible to restenosis, requiring frequent interventions to maintain patency. Stent-grafts (SGs) have been shown to improve patency and are already approved for use in this setting. This study aims to compare the off-label use of drug-eluting stents (DESs) versus SGs in managing hemodialysis vascular access outflow stenosis. MATERIALS AND METHODS: This single-center retrospective study reviewed patients treated with DES or SG for vascular access outflow stenosis. The primary outcome was the comparison of patency rates between DES and SG groups. RESULTS: A total of 156 patients were treated with either DES (n = 60 DES) or SG (n = 106 SG). DES deployment significantly reduced the mean number of target-lesion interventions (TLI) from 2.4 to 0.7 per year (p<0.001) and extended median TLI-free time from 4 to 10 months (p<0.001). Similarly, SG reduced mean TLI from 1.3 to 0.7 per year (p<0.001), increasing TLI-free time from 4 to 13 months (p<0.001). At 12 months, DES primary, assisted primary, and secondary patency rates were 49.9%, 78.2%, and 96.7%, respectively, compared to 58.8% (p=0.198), 72.3% (p=0.264), and 96.9% (p=0.877) for SGs. CONCLUSION: DES and SG significantly reduced TLI rates and prolonged TLI-free intervals compared to plain balloon angioplasty (PBA). No significant differences in overall patency were observed between the devices. These findings support DES as a potential alternative for managing outflow stenosis, particularly in venous confluent sites, where the risk of outflow jailing may compromise future vascular access.Clinical ImpactThis study suggests a potential paradigm shift in managing venous outflow lesions in dialysis access. By demonstrating comparable patency between drug-eluting stents (DES) and stent-grafts (SG), it broadens clinicians' options, particularly in anatomically challenging or recurrent stenoses. The innovation lies in identifying DES as a viable, off-label alternative that preserves future access possibilities by avoiding venous "jailing," a limitation of SGs. For clinicians, this means a more flexible, patient-tailored endovascular strategy that extends time to reintervention, optimizes long-term patency, and supports access preservation-especially valuable in cases requiring future surgical options like brachiobasilic fistula creation.
引用
- Pinelo A, Loureiro L, Mendes D, et al. Drug-Eluting Stents vs. Stent-Grafts in Hemodialysis Vascular Access Outflow Interventions. J Endovasc Ther. 2025. PMID: 41165335. doi:10.1177/15266028251384926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。